Literature DB >> 24081120

On the mechanism and benefit of siRNA-mediated targeting of CD47 in cancer.

Xiwen Zhao1, Hanke Matlung, Taco W Kuijpers, Timo K van den Berg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24081120      PMCID： PMC3808138          DOI： 10.1038/mt.2013.205

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  16 in total

1.  Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; Max Jan; Rachel Weissman-Tsukamoto; Feifei Zhao; Christopher Y Park; Irving L Weissman; Ravindra Majeti
Journal:  Cancer Res       Date:  2010-12-21       Impact factor: 12.701

2.  CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

Authors:  Siddhartha Jaiswal; Catriona H M Jamieson; Wendy W Pang; Christopher Y Park; Mark P Chao; Ravindra Majeti; David Traver; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

3.  Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma.

Authors:  Mark P Chao; Ash A Alizadeh; Chad Tang; June H Myklebust; Bindu Varghese; Saar Gill; Max Jan; Adriel C Cha; Charles K Chan; Brent T Tan; Christopher Y Park; Feifei Zhao; Holbrook E Kohrt; Raquel Malumbres; Javier Briones; Randy D Gascoyne; Izidore S Lossos; Ronald Levy; Irving L Weissman; Ravindra Majeti
Journal:  Cell       Date:  2010-09-03       Impact factor: 41.582

4.  Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy.

Authors:  Mark P Chao; Chad Tang; Russell K Pachynski; Robert Chin; Ravindra Majeti; Irving L Weissman
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

5.  CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

Authors:  Xi Wen Zhao; Ellen M van Beek; Karin Schornagel; Hans Van der Maaden; Michel Van Houdt; Marielle A Otten; Pascal Finetti; Marjolein Van Egmond; Takashi Matozaki; Georg Kraal; Daniel Birnbaum; Andrea van Elsas; Taco W Kuijpers; Francois Bertucci; Timo K van den Berg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-31       Impact factor: 11.205

6.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors.

Authors:  Stephen B Willingham; Jens-Peter Volkmer; Andrew J Gentles; Debashis Sahoo; Piero Dalerba; Siddhartha S Mitra; Jian Wang; Humberto Contreras-Trujillo; Robin Martin; Justin D Cohen; Patricia Lovelace; Ferenc A Scheeren; Mark P Chao; Kipp Weiskopf; Chad Tang; Anne Kathrin Volkmer; Tejaswitha J Naik; Theresa A Storm; Adriane R Mosley; Badreddin Edris; Seraina M Schmid; Chris K Sun; Mei-Sze Chua; Oihana Murillo; Pradeep Rajendran; Adriel C Cha; Robert K Chin; Dongkyoon Kim; Maddalena Adorno; Tal Raveh; Diane Tseng; Siddhartha Jaiswal; Per Øyvind Enger; Gary K Steinberg; Gordon Li; Samuel K So; Ravindra Majeti; Griffith R Harsh; Matt van de Rijn; Nelson N H Teng; John B Sunwoo; Ash A Alizadeh; Michael F Clarke; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

7.  Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.

Authors:  Justin B Maxhimer; David R Soto-Pantoja; Lisa A Ridnour; Hubert B Shih; William G Degraff; Maria Tsokos; David A Wink; Jeff S Isenberg; David D Roberts
Journal:  Sci Transl Med       Date:  2009-10-21       Impact factor: 17.956

8.  Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.

Authors:  Yuhua Wang; Zhenghong Xu; Shutao Guo; Lu Zhang; Arati Sharma; Gavin P Robertson; Leaf Huang
Journal:  Mol Ther       Date:  2013-06-18       Impact factor: 11.454

9.  CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells.

Authors:  Ravindra Majeti; Mark P Chao; Ash A Alizadeh; Wendy W Pang; Siddhartha Jaiswal; Kenneth D Gibbs; Nico van Rooijen; Irving L Weissman
Journal:  Cell       Date:  2009-07-23       Impact factor: 41.582

10.  Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies.

Authors:  Kipp Weiskopf; Aaron M Ring; Chia Chi M Ho; Jens-Peter Volkmer; Aron M Levin; Anne Kathrin Volkmer; Engin Ozkan; Nathaniel B Fernhoff; Matt van de Rijn; Irving L Weissman; K Christopher Garcia
Journal:  Science       Date:  2013-05-30       Impact factor: 47.728
View more
  2 in total

1.  Reply to "On the mechanism and benefit of siRNA-mediated targeting of CD47 in cancer".

Authors:  Yuhua Wang; Zhenghong Xu; Leaf Huang
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

Review 2.  Tumor-associated macrophages and anti-tumor therapies: complex links.

Authors:  Cristina Belgiovine; Maurizio D'Incalci; Paola Allavena; Roberta Frapolli
Journal:  Cell Mol Life Sci       Date:  2016-03-08       Impact factor: 9.261
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.